Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bicycle Therapeutics plc - American Depositary Shares
(NQ:
BCYC
)
13.31
-0.86 (-6.07%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 10, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
300,364
Open
13.98
Bid (Size)
12.11 (11)
Ask (Size)
14.73 (1)
Prev. Close
14.17
Today's Range
13.20 - 13.99
52wk Range
12.17 - 28.67
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 09, 2025
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2025
From
Bicycle Therapeutics plc
Via
Business Wire
Performance
YTD
-7.31%
-7.31%
1 Month
-33.81%
-33.81%
3 Month
-49.18%
-49.18%
6 Month
-41.11%
-41.11%
1 Year
-27.86%
-27.86%
More News
Read More
Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday
December 18, 2024
Via
Benzinga
Breaking Down Bicycle Therapeutics: 8 Analysts Share Their Views
December 16, 2024
Via
Benzinga
Navigating 11 Analyst Ratings For Bicycle Therapeutics
October 24, 2024
Via
Benzinga
In-Depth Examination Of 5 Analyst Recommendations For Bicycle Therapeutics
September 06, 2024
Via
Benzinga
The Latest Analyst Ratings For Bicycle Therapeutics
August 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 13, 2024
Via
Benzinga
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session
December 13, 2024
Via
Benzinga
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients
December 13, 2024
Via
Benzinga
Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification
December 12, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts
December 10, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update
November 25, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference
November 12, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
October 31, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals
October 23, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 Congress
October 16, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
BCYC: A Promising Play In The Biotech Sector
October 01, 2024
Via
Talk Markets
Topics
ETFs
Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024
September 14, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone
September 06, 2024
Via
Benzinga
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 03, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
August 21, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.